Andy Geall Email & Phone Number

Carlsbad, Ca, Us

• Technical evaluations on the mRNA vaccine landscape, mRNA production and purification, and non-viral delivery systems

• After sitting of the Scientific Advisory Board for 4 years, transitioned to full-time CSO • Responsible for Research and Development• Integral part of the Executive Team that enabled acquisition of the Company by Danaher in June 2021 • The company is focused on the creation of transformative nanoparticle medicines with its partners using PNI’s proprietary LNP delivery systems and microfluidic formulation platform• Secured Canadian Government funding (CAD $43.3 M) to develop an in-country mRNA vaccine pandemic response platform

San Diego, California, Us

• Member of the Executive Management, which successfully raised over $100 million in venture capital and took the company public in June 2020, with an initial public stock offering of $259 million• Helped create and direct a highly talented research team, which in 3 years established an extensive antibody oligonucleotide conjugate patent portfolio, enabling clinical applications and collaborative partnerships in rare muscle diseases• In addition to directing the chemistry and formulation research activities, responsible for CMC and outsourcing of clinical trial material production

• Internal transfer to the vaccines division to lead and pioneer the exploration of mRNA vaccines as a novel synthetic nucleic acid platform technology• Created at global team (USA/ Italy), which has established an extensive patent portfolio and explored the use of the technology in multiple disease targets • Co-ordinated and lead efforts to secure a $14.2 M award from the Defence Advanced Research Project Agency (DARPA) to develop self-amplifying mRNA vaccines. Currently the Principal Investigator on the contract, which is now entering its third year • Currently leading the technical transfer of mRNA vaccines into early exploratory clinical development• Part of the senior executive team at the Vaccine Research site in Cambridge• Responsible for securing future external funding to support advancement of the mRNA platform • Member of the joint steering committee of several external collaborations

• Laboratory head in Cambridge and global siRNA formulation team leader for sixteen research scientists based in the USA and Switzerland • Responsible for design and implementation of siRNA delivery strategy• Novartis senior expert on siRNA delivery systems, providing technical expertise on a global level to functional groups including, Research, Pharmaceutical Development, Legal/Patents, Analytical Development and Regulatory Affairs.

• Recruited to establish and lead the siRNA delivery group within CPP• Established a global team of sixteen research scientists

• Directed day-to-day operations of the Pharmaceutics Department, supervised formulation development of Vical’s investigational drug products and production of clinical trial material• Managed GMP synthesis of Vical’s proprietary cationic lipids and coordinate technology transfer to enable contract manufacturing• Responsible for discovery and development of new formulation technologies, writing feasibility and development proposals, comprehensive and conclusive project reports, scientific specifications for patent applications and relevant sections of FDA submissions

• Recruited by the CSO to develop a poloxamer-based DNA delivery system to enhance Vical’s gene vaccine platform. This goal was successfully achieved and the technology is now completing Phase II clinical trials• 4 patents have been filed on this delivery system

• Responsible for sales and marketing of a multi-million dollar marine retail business

Doctor Of Philosophy (Ph.D.), Gene Delivery Systems

Postdoctoral Researcher, Malaria

Postdoctoral Researcher, Gene Delivery

Mrpharms, Clinical, Hospital, And Managed Care Pharmacy

Bachelor'S Degree, Pharmacy

Bachelor'S Degree, Chemical Engineering